December 18, 2024
Teva Pharmaceuticals USA Inc. has failed to invalidate claims in a patent for a Johnson & Johnson unit's blockbuster schizophrenia medicine, according to a New Jersey federal judge who rejected the generic-drug maker's assertions that the formula was obvious.
August 05, 2024
Following a Federal Circuit ruling that gave generics makers Teva and Viatris a new shot at trying to invalidate the last remaining patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna, the parties are sparring over the impact of the appeals court's decision.
April 01, 2024
A Federal Circuit panel on Monday gave generics-makers Teva Pharmaceuticals USA Inc. and Viatris Inc. a new chance to prove that a patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna is invalid, saying a lower court used an "erroneously rigid" analysis when rejecting their challenge.
June 10, 2021
A New Jersey federal judge took the unusual step of reversing an order telling the U.S. Patent and Trademark Office to add two inventors to a Janssen Pharmaceuticals Inc. patent after its rival Teva informed the court that it had never consented to the inventors' addition.
January 18, 2018
A generic version of the schizophrenia drug Invega Sustenna that Teva Pharmaceuticals seeks to manufacture and sell would infringe the asserted claims of a patent covering the drug, Janssen Pharmaceuticals Inc. alleged Wednesday in New Jersey federal court.